TSVT News and Press, 2seventy bio Inc. From 01/30/24

- Company to focus exclusively on commercialization and development of Abecma , in partnership with Bristol Myers Squibb - - Company to sell R&D pipeline to Regeneron to launch Regeneron Cell Medicines business led by 2seventy bio’s Chief Scientific Officer, Philip Greg...

2024-01-26 08:09:58 ET More on Bristol-Myers Bristol Myers Squibb: Might Be Approaching A Bottom In 2024 Bristol-Myers Squibb: Big Dividend Yield, Unloved Big-Pharma Deal Bristol-Myers Squibb: I Went Looking For Value And Found A 4.63% Yield Also Bristol Myer...

2024-01-22 23:09:28 ET More on J&J and Bristol-Myers Squibb Johnson & Johnson: Is The Dividend Still Safe After The Kenvue Split-Off? Johnson & Johnson Remains A Safe Bet Amidst Talc Lawsuits And Ambrx Acquisition Bristol-Myers Squibb: Big Dividend Yiel...

2024-01-09 16:27:39 ET Summary 2seventy bio has experienced a significant decline in stock value, down 70% since June 2023. The FDA has delayed the approval of TSVT's CAR-T cell therapy Abecma for earlier lines of multiple myeloma due to a planned advisory committee meeting. T...

2024-01-07 04:45:00 ET Summary Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Suzhou MediLink Therapeutics out-licensed global rights for its pre-clinical c-Mesenchymal epithelial transition factor ADC to R...

2023-12-31 02:49:47 ET Summary Bristol-Myers Squibb is a well-known blue-chip stock with a dividend yield exceeding 4.6%. Since 2019, Bristol-Myers Squibb has acquired pharmaceutical companies worth more than $115 billion, allowing it to expand its drug portfolio and product candi...

2023-12-26 10:02:19 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tu...

At median follow-up of more than 30 months, Abecma maintained a 51% reduction in risk of disease progression or death with median PFS of 13.8 months compared with 4.4 months for standard regimens Responses were significantly improved with Abecma and continued to deepen over ti...

2seventy bio, Inc . (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, announced today that the Company will host a conference call on Tuesday, December 12, 2023, at 8:00am ET. The event will highlight data presented at the 65 th American Society of Hematology (ASH) Annual Meet...

2023-12-08 16:43:19 ET Gainers: IGM Biosciences, Inc. ( IGMS ) +9% . EF Hutton Acquisition Corporation I ( EFHT ) +6% . Biomea Fusion ( BMEA ) +5% . Larimar Therapeutics ( LRMR ) +2% . First Solar ( FSLR ) +1% . Losers: L...